Duke Energy Corp vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Duke Energy Corp trades at $116.58 (market cap $91.10B), while Halozyme Therapeutics Inc. Common Stock trades at $112.45 (market cap $12.58B). The key difference: Duke Energy Corp is far larger — about 7.2× Halozyme Therapeutics Inc. Common Stock's market cap, and Duke Energy Corp pays a 3.71% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| DUK | HALO | |
|---|---|---|
Market Cap | $91.10B | $12.58B |
Volume | 4,199,050 | 2,179,278 |
Sector | Utilities | Health |
52-Week High | $133.46 | $115.22 |
52-Week Low | $113.23 | $61.63 |
Enterprise Value | $183.61B | $14.49B |
Dividend Yield | 3.71% | — |
Typical Hold Time | — | 0 Days |
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $116.55, up 0.91% today, with a bullish technical signal despite mixed moving averages. The company shows consistent earnings beats, with Q2 2026 EPS of $1.43 exceeding the $1.30 estimate. Revenue grew to $32.24B in 2025, and net income margin improved to 15.78%. Recent news highlights dividend declarations and data center growth opportunities, though rising Treasury yields pose a headwind for utility stocks.
DUK offers a stable dividend and benefits from data center demand, but high debt levels and interest rate sensitivity present risks. Analyst consensus is a Buy with a $134.44 price target, implying 15% upside. The stock's valuation is reasonable with a P/E of 17.6, supporting a cautious bullish outlook amid macroeconomic pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →